Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros












Base de dados
Intervalo de ano de publicação
1.
Int J Mol Sci ; 25(7)2024 Mar 28.
Artigo em Inglês | MEDLINE | ID: mdl-38612604

RESUMO

Metastasis and drug resistance are major contributors to cancer-related fatalities worldwide. In ovarian cancer (OC), a staggering 70% develop resistance to the front-line therapy, cisplatin. Despite proposed mechanisms, the molecular events driving cisplatin resistance remain unclear. Dysregulated microRNAs (miRNAs) play a role in OC initiation, progression, and chemoresistance, yet few studies have compared miRNA expression in OC samples and cell lines. This study aimed to identify key miRNAs involved in the cisplatin resistance of high-grade-serous-ovarian-cancer (HGSOC), the most common gynecological malignancy. MiRNA expression profiles were conducted on RNA isolated from formalin-fixed-paraffin-embedded human ovarian tumor samples and HGSOC cell lines. Nine miRNAs were identified in both sample types. Targeting these with oligonucleotide miRNA inhibitors (OMIs) reduced proliferation by more than 50% for miR-203a, miR-96-5p, miR-10a-5p, miR-141-3p, miR-200c-3p, miR-182-5p, miR-183-5p, and miR-1206. OMIs significantly reduced migration for miR-183-5p, miR-203a, miR-296-5p, and miR-1206. Molecular pathway analysis revealed that the nine miRNAs regulate pathways associated with proliferation, invasion, and chemoresistance through PTEN, ZEB1, FOXO1, and SNAI2. High expression of miR-1206, miR-10a-5p, miR-141-3p, and miR-96-5p correlated with poor prognosis in OC patients according to the KM plotter database. These nine miRNAs could be used as targets for therapy and as markers of cisplatin response.


Assuntos
MicroRNAs , Neoplasias Ovarianas , Humanos , Feminino , MicroRNAs/genética , Cisplatino/farmacologia , Cisplatino/uso terapêutico , Neoplasias Ovarianas/tratamento farmacológico , Neoplasias Ovarianas/genética , Linhagem Celular , Oligonucleotídeos
2.
ACS Omega ; 7(4): 3731-3737, 2022 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-35128281

RESUMO

Liposomes are among the most effective vehicles to deliver siRNAs to cells, both in vitro and in vivo. However, despite numerous efforts to improve the potential of liposomes, siRNAs begin to leach out of liposomes as soon as they are formulated. This decreases the value of liposomes for drug delivery purposes significantly, masking their true potential. In this study, we examine the effect of ß-cyclodextrins on the retention time and transfection efficiency of siRNAs formulated in a liposome. Cyclodextrins have been widely studied as solvating agents and drug delivery vectors mainly because these cyclic nontoxic glucose structures can bind several molecules of different physicochemical characteristics, through H-bonding or by forming inclusion complexes. These properties, although beneficial for most applications, have resulted in some contradictory results published in the literature, whereas cyclodextrins have been found to destabilize a liposome's membrane. Here, we present a systematic study, which shows that ß-cyclodextrin binds, possibly via hydrogen bonding, with siRNA and DOPC liposomes, resulting in increased siRNA serum stability and in vitro siRNA's transfection efficiency when formulated together.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...